Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 534

1.

New benzothiazole/thiazole-containing hydroxamic acids as potent histone deacetylase inhibitors and antitumor agents.

Tung TT, Oanh DT, Dung PT, Hue VT, Park SH, Han BW, Kim Y, Hong JT, Han SB, Nam NH.

Med Chem. 2013 Dec;9(8):1051-7.

PMID:
23521008
2.

Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents.

Oanh DT, Hai HV, Park SH, Kim HJ, Han BW, Kim HS, Hong JT, Han SB, Hue VT, Nam NH.

Bioorg Med Chem Lett. 2011 Dec 15;21(24):7509-12. doi: 10.1016/j.bmcl.2011.07.124. Epub 2011 Aug 6.

PMID:
22036991
3.

5-aryl-1,3,4-thiadiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents: synthesis, bioevaluation and docking study.

Huong TT, Dung do TM, Oanh DT, Lan TT, Dung PT, Loi VD, Kim KR, Han BW, Yun J, Kang JS, Kim Y, Han SB, Nam NH.

Med Chem. 2015;11(3):296-304.

PMID:
25256241
4.

Novel isatin-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents.

Nam NH, Huong TL, Dung do TM, Dung PT, Oanh DT, Quyen D, Thao le T, Park SH, Kim KR, Han BW, Yun J, Kang JS, Kim Y, Han SB.

Eur J Med Chem. 2013;70:477-86. doi: 10.1016/j.ejmech.2013.10.045. Epub 2013 Oct 23.

PMID:
24185378
5.

Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.

Guan P, Sun F, Hou X, Wang F, Yi F, Xu W, Fang H.

Bioorg Med Chem. 2012 Jun 15;20(12):3865-72. doi: 10.1016/j.bmc.2012.04.032. Epub 2012 Apr 21.

PMID:
22579621
6.

Effect of C7-substitution of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines on the selectivity towards a subclass of histone deacetylases.

Lee HY, Wang LT, Li YH, Pan SL, Chen YL, Teng CM, Liou JP.

Org Biomol Chem. 2014 Nov 28;12(44):8966-76. doi: 10.1039/c4ob00542b.

PMID:
25277250
7.

Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.

Cai J, Wei H, Hong KH, Wu X, Cao M, Zong X, Li L, Sun C, Chen J, Ji M.

Eur J Med Chem. 2015;96:1-13. doi: 10.1016/j.ejmech.2015.04.002. Epub 2015 Apr 6.

PMID:
25874326
8.

New aryldithiolethione derivatives as potent histone deacetylase inhibitors.

Tazzari V, Cappelletti G, Casagrande M, Perrino E, Renzi L, Del Soldato P, Sparatore A.

Bioorg Med Chem. 2010 Jun 15;18(12):4187-94. doi: 10.1016/j.bmc.2010.05.011. Epub 2010 May 7.

PMID:
20576572
9.

Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.

Cincinelli R, Musso L, Giannini G, Zuco V, De Cesare M, Zunino F, Dallavalle S.

Eur J Med Chem. 2014 May 22;79:251-9. doi: 10.1016/j.ejmech.2014.04.021. Epub 2014 Apr 8.

PMID:
24742384
10.

Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.

Chen Y, Wang X, Xiang W, He L, Tang M, Wang F, Wang T, Yang Z, Yi Y, Wang H, Niu T, Zheng L, Lei L, Li X, Song H, Chen L.

J Med Chem. 2016 Jun 9;59(11):5488-504. doi: 10.1021/acs.jmedchem.6b00579. Epub 2016 May 24.

PMID:
27186676
11.

Novel 3-substituted-2-oxoindoline-based N-hydroxypropenamides as histone deacetylase inhibitors and antitumor agents.

Dung do TM, Dung PT, Oanh DT, Hai PT, Huong le TT, Loi VD, Hahn H, Han BW, Kim J, Han SB, Nam NH.

Med Chem. 2015;11(8):725-35.

PMID:
26133355
12.

Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors.

Liu R, Wang J, Tang W, Fang H.

Bioorg Med Chem. 2016 Apr 1;24(7):1446-54. doi: 10.1016/j.bmc.2016.02.005. Epub 2016 Feb 6.

PMID:
26907204
13.

Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity.

Chetan B, Bunha M, Jagrat M, Sinha BN, Saiko P, Graser G, Szekeres T, Raman G, Rajendran P, Moorthy D, Basu A, Jayaprakash V.

Bioorg Med Chem Lett. 2010 Jul 1;20(13):3906-10. doi: 10.1016/j.bmcl.2010.05.020. Epub 2010 May 15.

PMID:
20605448
14.

Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.

Li X, Hou J, Li X, Jiang Y, Liu X, Mu W, Jin Y, Zhang Y, Xu W.

Eur J Med Chem. 2015 Jan 7;89:628-37. doi: 10.1016/j.ejmech.2014.10.077. Epub 2014 Oct 29.

PMID:
25462271
15.

Design, synthesis and biological evaluation of indeno[1,2-d]thiazole derivatives as potent histone deacetylase inhibitors.

Zhou M, Ning C, Liu R, He Y, Yu N.

Bioorg Med Chem Lett. 2013 Jun 1;23(11):3200-3. doi: 10.1016/j.bmcl.2013.04.004. Epub 2013 Apr 11.

PMID:
23639537
16.

Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.

Suzuki T, Nagano Y, Kouketsu A, Matsuura A, Maruyama S, Kurotaki M, Nakagawa H, Miyata N.

J Med Chem. 2005 Feb 24;48(4):1019-32.

PMID:
15715470
17.

Synthesis and antitumor activity of novel diaryl ether hydroxamic acids derivatives as potential HDAC inhibitors.

Zhu Y, Chen X, Wu Z, Zheng Y, Chen Y, Tang W, Lu T.

Arch Pharm Res. 2012 Oct;35(10):1723-32. doi: 10.1007/s12272-012-1003-0. Epub 2012 Nov 9.

PMID:
23139122
18.

Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.

Angibaud P, Van Emelen K, Decrane L, van Brandt S, Ten Holte P, Pilatte I, Roux B, Poncelet V, Speybrouck D, Queguiner L, Gaurrand S, Mariën A, Floren W, Janssen L, Verdonck M, van Dun J, van Gompel J, Gilissen R, Mackie C, Du Jardin M, Peeters J, Noppe M, Van Hijfte L, Freyne E, Page M, Janicot M, Arts J.

Bioorg Med Chem Lett. 2010 Jan 1;20(1):294-8. doi: 10.1016/j.bmcl.2009.10.118. Epub 2009 Oct 30.

PMID:
19906529
19.

Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects.

Liao V, Liu T, Codd R.

Bioorg Med Chem Lett. 2012 Oct 1;22(19):6200-4. doi: 10.1016/j.bmcl.2012.08.006. Epub 2012 Aug 9.

PMID:
22932316
20.

The discovery of colchicine-SAHA hybrids as a new class of antitumor agents.

Zhang X, Zhang J, Tong L, Luo Y, Su M, Zang Y, Li J, Lu W, Chen Y.

Bioorg Med Chem. 2013 Jun 1;21(11):3240-4. doi: 10.1016/j.bmc.2013.03.049. Epub 2013 Mar 31.

PMID:
23602523

Supplemental Content

Support Center